Dr. Öğr. Üyesi ATİLA YILDIRIM

1. Prognostic impact of pathological complete response in hormone receptor–positive/HER2-negative breast cancer treated with neoadjuvant chemotherapy: a multicenter cohort study

Uguztemur E., Arici O., Asik E., Karanci E., YILDIRIM A.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

2. Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

Atas Ipek S., Yaslikaya S., KARA İ. O., KÖŞECİ T., BAYRAM E., Asarkaya E., et al.

Journal of Clinical Medicine , cilt.15, sa.13, 2026 (SCI-Expanded, Scopus)

3. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

Köylü B., Celayir Ö. M., Muğlu H., Can O., Şen F., Öven B. B., et al.

Cancers , cilt.18, sa.12, 2026 (SCI-Expanded, Scopus)

4. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

Seyyar M., Can Şancı P., SAKİN A., Bayramgil A., Dülgar Kaya Ö., SÜNGER E., et al.

Medicina (Lithuania) , cilt.62, sa.5, 2026 (SCI-Expanded, Scopus)

5. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

Yıldız S., Demir H., Özüdoğru T., Günenç D., Gökdere Z. S., Arvas H., et al.

Journal of Clinical Medicine , cilt.15, sa.6, 2026 (SCI-Expanded, Scopus)

6. Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)

Akkus E., Kayaalp M., Ergözoğlu M. A., Koç Kuş I., Bayram D., Kılıçtaş B., et al.

JCO global oncology , cilt.12, sa.3, 2026 (ESCI, Scopus)

7. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

KÖKSAL B., Yildirim H. C., GÜVEN D. C., Kose F., Koymen G., Ozdemir O., et al.

Journal of Clinical Medicine , cilt.15, sa.4, 2026 (SCI-Expanded, Scopus)

8. Altered Apoptosis in Endometriosis Compared with Ovarian Carcinoma

Ozdemir O., YILDIRIM A., TEKELİOĞLU Y., ERSÖZ Ş., GÜVEN S.

Medicina (Lithuania) , cilt.61, sa.11, 2025 (SCI-Expanded, Scopus)

9. CDK4/6 Inhibitor-Associated Mean Corpuscular Volume Change: A Potential Parameter for Predicting Survival in Metastatic Breast Cancer?

Yildirim A., DUYGULU M. E., FİDAN E.

Journal of the College of Physicians and Surgeons Pakistan , cilt.34, sa.7, ss.785-789, 2024 (SCI-Expanded, Scopus)

10. The Effect of Chemotherapeutic Agents on Survival in Metastatic Non-Small-Cell Lung Cancer with KRAS Mutation

DUYGULU M. E., YILDIRIM A., AYAS E., ALYILDIZ N., Mungan S., FİDAN E.

INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY , cilt.45, sa.2, ss.127-133, 2024 (ESCI, Scopus)

11. Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung

DUYGULU M. E., AŞIK E., TÜKENMEZ M. A., TEOMAN G., Yildirim A., FİDAN E.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA , cilt.70, sa.9, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

12. Evaluation of patient adherence with oral anticancer agents

Kazaz S. N., Yıldırım A.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.20, sa.10.4103/jcrt.jcrt_2238_22, ss.1707-1712, 2024 (SCI-Expanded, Scopus)

13. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?

Kazaz S. N., Özdöver A. C., Usta N., Yıldırım A., Fidan E., Özdemir F.

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN , cilt.33, sa.6, ss.659-665, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Anxiety Levels in Cancer Patients during the First Months of the COVID-19 Pandemic

KAZAZ S. N., YILDIRIM A.

Sağlık bilimlerinde değer (Online) , cilt.13, sa.1, ss.87-92, 2023 (TRDizin)

15. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

Yekeduz E., ÖZBAY M. F., Caglayan D., YILDIRIM A., Erol C., YILDIRIM H. Ç., et al.

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY , cilt.78, sa.12, ss.1973-1979, 2022 (SCI-Expanded, Scopus)

16. Hearing Loss After the First Low Dose Administration of Cisplatin

YILDIRIM A., FİDAN E., ÖZDEMİR F.

JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN , cilt.32, sa.9, ss.1216-1218, 2022 (SCI-Expanded, Scopus)

17. The relationship between albumin-bilirubin score and survival in patients operated for pancreatic cancer

FİDAN E., Yildirim A., Kazaz N., FİDAN S., ÇEKİÇ A. B.

JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION , cilt.72, sa.7, ss.1340-1344, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

18. Evaluation of knowledge, attitudes and behaviors about COVID-19 among cancer patients

KAZAZ S. N., YILDIRIM A.

ANNALS OF CLINICAL AND ANALYTICAL MEDICINE , sa.4, ss.389-393, 2022 (ESCI)

19. Gingival Stimulation: An Important Metabolic Regulator?

A Y., H A., A B., I D.

Journal of Obesity and Overweight , cilt.3, sa.2, ss.199-204, 2017 (Hakemli Dergi)

Dr. Öğr. Üyesi ATİLA YILDIRIM

Yayınlar & Eserler

1. Prognostic impact of pathological complete response in hormone receptor–positive/HER2-negative breast cancer treated with neoadjuvant chemotherapy: a multicenter cohort study

2. Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

3. Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study

4. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

5. Tyrosine Kinase Inhibitor Therapy in Metastatic Medullary Thyroid Carcinoma: Real-World Data from Turkish Oncology Group

6. Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)

7. Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis

8. Altered Apoptosis in Endometriosis Compared with Ovarian Carcinoma

9. CDK4/6 Inhibitor-Associated Mean Corpuscular Volume Change: A Potential Parameter for Predicting Survival in Metastatic Breast Cancer?

10. The Effect of Chemotherapeutic Agents on Survival in Metastatic Non-Small-Cell Lung Cancer with KRAS Mutation

11. Effect of Ki-67 proliferation index on survival in large cell neuroendocrine carcinoma of the lung

12. Evaluation of patient adherence with oral anticancer agents

13. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?

14. Anxiety Levels in Cancer Patients during the First Months of the COVID-19 Pandemic

15. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study

16. Hearing Loss After the First Low Dose Administration of Cisplatin

17. The relationship between albumin-bilirubin score and survival in patients operated for pancreatic cancer

18. Evaluation of knowledge, attitudes and behaviors about COVID-19 among cancer patients

19. Gingival Stimulation: An Important Metabolic Regulator?

Yayın

Yayın (WoS)

Yayın (Scopus)

Atıf (WoS)

H-İndeks (WoS)

Atıf (Scopus)

H-İndeks (Scopus)

Tez Danışmanlığı

Açık Erişim